Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 1,98 MB, PDF-dokument
Introduction: The pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) has emerged as a key mediator of migraine pathogenesis. PACAP-38 and its receptors are predominantly distributed in arteries, sensory and parasympathetic neurons of the trigeminovascular system. Phase 2 trials have tested human monoclonal antibodies designed to bind and inhibit PACAP-38 and the pituitary adenylate cyclase-activating polypeptide type I (PAC1) receptor for migraine prevention. Areas covered: This review focuses on the significance of the PACAP-38 pathway as a target in migraine prevention. English peer-reviewed articles were searched in PubMed, Scopus and ClinicalTrials.gov electronic databases. Expert opinion: A PAC1 receptor monoclonal antibody was not effective for preventing migraine in a proof-of-concept trial, paving the way for alternative strategies to be considered. Lu AG09222 is a humanized monoclonal antibody targeting PACAP-38 that was effective in preventing physiological responses of PACAP38 and reducing monthly migraine days in individuals with migraine. Further studies are necessary to elucidate the clinical utility, long-term safety and cost-effectiveness of therapies targeting the PACAP pathway.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Expert Opinion on Emerging Drugs |
Vol/bind | 29 |
Udgave nummer | 1 |
Sider (fra-til) | 57-64 |
Antal sider | 8 |
ISSN | 1472-8214 |
DOI | |
Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:
This paper was not funded.
Publisher Copyright:
© 2024 Informa UK Limited, trading as Taylor & Francis Group.
ID: 390186761